Compounds of the formula ##STR00001## where the variables are as defined
in the specification inhibit the NS3 protease of flavivirus such as
hepatitis C virus (HCV). The compounds comprise a novel linkage between a
heterocyclic P2 unit and those portions of the inhibitor more distal to
the nominal cleavage site of the native substrate, which linkage reverses
the orientation of peptidic bonds on the distal side relative to those
proximal to the cleavage site.